|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical trial of antiangiogenie agents显示文摘 | Twardowski P Gradishar W J | 1997 | Curr Opin Oncol1997，9，6： | 1 |
| 2 | Management of advanced breast cancer with the epothilone B analog, ixabepilone 显示文摘 | Gradishar W | 2009 | Drug Design Development and Therapy2009，3，： | 1 |
| 3 | Recently initiated studies: neoadjuvant treatments in next century 显示文摘 | Gradishar W J | 1999 | Semi Oncol1999，26，13： | 1 |
| 4 | Eribulinmesylate 显示文摘 | HUYCK T K GRADISHAR W MANUGUID F | 2011 | Nat Rev Drug Discov2011，10，3： | 1 |
| 5 | PhaseIII trial of nanoparticle albumin-bound paclitaxel compared withpolyethylated castor oil-based paclitaxel in women with breastcancer显示文摘 | GRADISHAR W J TJULANDIN S DAVIDSON N | 2005 | Clin Oncol2005，23，31： | 1 |
| 6 | Effects of highdose raloxifene in selected patients with advancedbreast carcinoma显示文摘 | GRADISHAR W GLUSMAN J LU Y | 2000 | Cancer2000，88，9： | 1 |
| 7 | Double -Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Ammatase Inhibitor Therapy in Postmenopa- usal Women With Hormone Receptor - Positive, Advanced Breast Cancer: Results From EFECT 显示文摘 | Chia S Gradishar W Mauriac L | 2008 | J Clin Oneol2008，26，10： | 1 |
| 8 | 5-Fluorouracil cardiotoxicity: a critical review显示文摘 | Gradishar W J Vokes E E | 1990 | Ann Oncol1990，1，6： | 1 |
| 9 | Landmark trials in endocrine adjuvant therapy for breast carcinoma显示文摘 | Gradishar W | 2006 | Cancer2006，106，5： | 1 |
| 10 | Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer : results from EFECT 显示文摘 | Chia S Gradishar W Mauriae L' | 2008 | J Clin Oncol2008，26，10： | 1 |
| 11 | Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer显示文摘 | GRADISHAR W J TJULANDIN S DAVIDSON N | 2005 | J Clin Oncol2005，23，31： | 1 |
| 12 | Evidence-driven, patient- specific approaches for optimizing survival prolongation in breast cancer显示文摘 | Gradishar W J Twelves C Rugo HS | 2014 | Clin Adv Hematol Oncol2014，12，815： | 1 |
| 13 | Significantly longer progression-free survival with nabpaclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer 显示文摘 | GRADISHAR W J KRASNOJON D CHEPOROV S | 2009 | J Clin Oncol2009，27，22： | 1 |
| 14 | Phase II trial of nab-paclitaxel compared with docetaxel as first-line chemotherapy in patients with metastatic breast cancer: final analysis of overall survival 显示文摘 | GRADISHAR W J KRASNOJON D CHEPOROV S | 2012 | Clin Breast Cancer2012，12，5： | 1 |
| 15 | Advances in endocrine therapy for the treatment and prevention of breast cancer显示文摘 | Gradishar W J Jordan VC | 2003 | Cancer Chemother Biol Response Modif2003，21，： | 1 |
| 16 | Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonstemidal ammatase inhibitor therapy in postmcnopansal women with hormone receptor-positive, advanced breast cancer: resuits from E FECT 显示文摘 | Chia S Gradishar W Mauriae L | 2008 | J C lin Oncol2008，26，10： | 1 |
| 17 | Phase Ⅲ trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer显示文摘 | Gradishar W J Tjulandin S Davidson N | 2005 | J Clin Oncol2005，23，31： | 1 |
| 18 | Albumin-bound paclitaxel: a next-generation taxane 显示文摘 | Gradishar W J | 2006 | Expert Opin Pharmacother2006，7，8： | 1 |
| 19 | Double - blind, randomized placebo controlled trial of fulvestrant compared with exemes- tane after prior nonsteriodal aromatase inhibitor therapy in postmenopausal women wilh hormone receptor positive, ad- vanced breast cancer: results from EFECT 显示文摘 | Chia S Gradishar W Mauriac L | 2008 | Clin Dncol2008，26，10： | 1 |
| 20 | Recently initiated studies:neoadjuvant treatments in the next century显示文摘 | Gradishar W J | 1999 | Semin Oncol1999，26，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员